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Abstract
Background: The ubiquitin-proteasome-system (UPS) is the major intracellular pathway leading to the degradation
of unwanted and/or misfolded soluble proteins. This includes proteins regulating cellular survival, synaptic plasticity
and neurotransmitter signaling; processes controlling excitability thresholds that are altered by epileptogenic insults.
Dysfunction of the UPS has been reported to occur in a brain region- and cell-specific manner and contribute to
disease progression in acute and chronic brain diseases. Prolonged seizures, status epilepticus, may alter UPS
function but there has been no systematic attempt to map when and where this occurs in vivo or to determine
the consequences of proteasome inhibition on seizure-induced brain injury.
Method: To determine whether seizures lead to an impairment of the UPS, we used a mouse model of status
epilepticus whereby seizures are triggered by an intra-amygdala injection of kainic acid. Status epilepticus in this
model causes cell death in selected brain areas, in particular the ipsilateral CA3 subfield of the hippocampus, and
the development of epilepsy after a short latent period. To monitor seizure-induced dysfunction of the UPS we
used a UPS inhibition reporter mouse expressing the ubiquitin fusion degradation substrate ubiquitinG76V-green
fluorescent protein. Treatment with the specific proteasome inhibitor epoxomicin was used to establish the impact
of proteasome inhibition on seizure-induced pathology.
Results and conclusions: Our studies show that status epilepticus induced by intra-amygdala kainic acid causes select
spatio-temporal UPS inhibition which is most evident in damage-resistant regions of the hippocampus, including CA1
pyramidal and dentate granule neurons then appears later in astrocytes. In support of this exerting a beneficial effect,
injection of mice with the proteasome inhibitor epoxomicin protected the normally vulnerable hippocampal CA3 subfield
from seizure-induced neuronal death in the model.
These studies reveal brain region- and cell-specific UPS impairment occurs after seizures and suggest UPS inhibition can
protect against seizure-induced brain damage. Identifying networks or pathways regulated through the proteasome after
seizures may yield novel target genes for the treatment of seizure-induced cell death and possibly epilepsy.
Keywords: Ubiquitin-proteasome system, Status epilepticus, Epilepsy, Proteasome inhibition, Neuroprotection,
Hippocampal sclerosis, Epileptogenesis
* Correspondence: tengel@rcsi.ie
1Department of Physiology & Medical Physics, Royal College of Surgeons in
Ireland, 111 St. Stephen’s Green, Dublin 02 YN77, Ireland
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Engel et al. Molecular Neurodegeneration  (2017) 12:21 
DOI 10.1186/s13024-017-0163-2
Background
The cell and molecular mechanisms by which injury to
the brain leads to the later emergence of chronic, spon-
taneous seizures, a process termed epileptogenesis, re-
mains incompletely understood [1]. Epileptogenesis is
associated with large-scale changes to gene expression
which is thought to impact on neuronal survival and to
drive remodelling of neuronal networks, aberrant neuro-
transmitter receptor expression and function, gliosis,
neuroinflammation and other characteristic changes [2].
It is increasingly recognized that targeting single genes is
unlikely to be sufficient to disrupt epileptogenesis and
ways to target larger signalling networks are required
[1]. This has driven a strong focus on transcription
factors and epigenetic mediators [3], systems genetics
approaches [4] and post-transcriptional gene silencing
by non-coding microRNAs [5]. This is apt because it is
mRNA transcription that provides the greatest contribu-
tion to the abundance of proteins during stress [6, 7]. In
contrast, protein turnover has been reported to contrib-
ute less than 10% to overall protein abundance [7].
Nevertheless, protein aggregates and dysfunction of the
molecular machinery responsible for regulating protein
turnover is evident in numerous neurodegenerative and
neurologic disorders [8–10]. Thus, protein turnover may
be especially important for the pathogenesis of diseases
associated with the brain. Whether altered protein turn-
over is important in epileptogenesis is unknown.
The ubiquitin proteasome system (UPS) is the major
intracellular pathway leading to the degradation of aberrant
and/or misfolded soluble proteins [11]. The UPS is a highly
conserved and tightly controlled ATP-consuming proteo-
lytic system. Ubiquitin (Ub) is first activated by an E1 en-
zyme, and then transferred to an ubiquitin-conjugating E2
enzyme [11]. Substrates to be degraded are selectively rec-
ognized by E3 Ub ligases [12]. E3 ligases mediate the subse-
quent transfer of activated Ubs from E2 to the substrate
leading to an increasing polyubiquitination chain [11].
Once Ub moieties reach four or more per substrate chain,
the substrate is usually recognized by the 26S proteasome
[13]. The 26S proteasome is composed of two 19S regula-
tory protein complexes important for substrate recognition
and deubiquitination and a barrel-like shaped 20S protein
complex with a catalytic core in charge of substrate cleav-
age into smaller peptides and amino acids [14].
The UPS is present and functions in multiple sub-cellular
compartments including cytoplasm, nucleus, mitochondria,
cell membranes and pre- and post-synaptic compartments
in neurons [15–17]. In the nervous system, the UPS has
been shown to regulate turnover of proteins critical for
neuronal survival and neurotransmission [16, 17] by
controlling the presence of functional glutamate [18] and γ-
amino butyric acid (GABA) receptor levels [19], spinogen-
esis [20], dendrite growth and arborisation [21] and the
formation of new synapses [22]. Proteasome inhibition has
been proposed to play a causative role in numerous acute
and chronic diseases of the brain including ischemia [10]
and neurodegenerative diseases such as Alzheimer’s,
Huntington’s and Parkinson’s [9, 23]. Consequently, UPS-
targeting drugs have been proposed as potential therapeutic
treatment strategies for various brain diseases [9].
Emerging evidence suggests the function and dysregula-
tion of the UPS is important in epilepsy. Glutamate-
induced excitotoxicity leads to an inhibition of the prote-
asome [24]. Genes linked to ubiquitin metabolism are
prominent among transcripts regulated by seizures in ani-
mal models [25]. The deubiquitinating enzyme USP9X
regulates excitability and seizures in animals and humans
[26]. Genetic or pharmacologic targeting of the E3 ubiqui-
tin ligase CRL4A (CRBN) increases seizure susceptibility
[27]. The immunoproteasome, a particular form of the
proteasome believed to play a key role during inflamma-
tion, is upregulated in brain tissue from patients with tem-
poral lobe epilepsy (TLE) [28] and in the hippocampus of
rats with chronic epilepsy [29]. Lafora disease, a progres-
sive myoclonic epilepsy characterized by the presence of
glycogen-like intracellular inclusions named Lafora bod-
ies, results from mutations in the ubiquitin E3 ligase malin
[30]. In addition, 20S proteasome subunits have been
shown to be sequestered in Lafora bodies [31]. Mutations
in the E3 ligase Ube3a have been shown to cause Angel-
man syndrome, a rare neurological disorder commonly as-
sociated with intractable seizures [32] and the E3 ligase
MDM2 controls levels of the transcription factor p53
which regulates cell death and seizure thresholds in ex-
perimental and human epilepsy [33, 34].
However, up to date there have been no studies carried
out to characterize where exactly UPS inhibition occurs
after seizures in vivo, which cell-types are involved and
whether proteasome inhibition impacts on seizure-
induced brain damage. Here we used a UPS inhibition
green fluorescent protein (GFP)-reporter mouse [35] to
map UPS inhibition in vivo following status epilepticus.
We also tested a proteasome inhibitor for effects on
seizure-induced neuronal death.
Results
Increase in polyubiquitinated conjugates in the
hippocampus after status epilepticus
To determine whether prolonged seizures (status epilep-
ticus) lead to an impairment of the UPS, we used our
well characterized mouse model of status epilepticus
[36]. In this model, status epilepticus is induced by a
unilateral microinjection of kainic acid (KA) into the
basolateral amygdala. Shortly after KA injection, mice
develop continuous electrographic seizures (status epi-
lepticus). To reduce morbidity and mortality, mice are
treated with the anticonvulsant lorazepam 40 min post-
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KA [36]. Increased transcript levels of the neuronal
activity-regulated gene c-Fos in the ipsilateral hippocam-
pus confirmed the recruitment of hippocampal struc-
tures during seizures (Additional file 1: Figure S1). In
this model, seizure-induced cell death is mainly re-
stricted to the ipsilateral hippocampus, in particular the
CA3 subfield, as detected by Fluoro-Jade B (FjB) staining
(Fig. 1a and [36]). The ipsilateral CA1 subfield and the
granule neurons of the dentate gyrus (DG) are typically
spared significant injury as are the subfields in the
contralateral hippocampus (Fig. 1a and [36]).
To investigate whether the model is associated with
an impairment of the UPS, we analyzed levels of polyu-
biquitinated conjugates in the ipsilateral hippocampus
at different time-points after status epilepticus. Western
blotting showed an early accumulation of polyubiquiti-
nated substrates shortly after status epilepticus (Fig. 1b).
To check this was not a model-specific characteristic,
we performed an analysis of the hippocampus of mice
subject to status epilepticus triggered by the muscarinic
agonist pilocarpine [37]. As with the intra-amygdala
KA model, pilocarpine-induced seizures resulted in
Fig. 1 Increased polyubiquitination after status epilepticus. a. Representative pictures of coronal brain sections at the level of the dorsal ipsilateral
and contralateral hippocampus 24 h after status epilepticus showing FjB-positive cells restricted mainly to the ipsilateral CA3 subfield (arrows and
insert). Note, the ipsilateral CA1 and dentate gyrus (DG) and the contralateral hippocampus are mainly spared from cell death. Scale bar, 500 μm
b. Representative Western (n = 1 per lane) and graph showing increased polyubiquitination levels (FK2 antibody) in the ipsilateral hippocampus
after intra-amygdala KA induced-status epilepticus (mean ± sem, *p <0.05 by one-way ANOVA with Fisher’s post hoc test; n = 4 per group). c.
Representative Western (n = 1 per lane) and graph showing increased polyubiquitination levels (FK2 antibody) in the hippocampus after
pilocarpine-induced status epilepticus (mean ± sem, *p <0.05 by student’s two-tailed t-test; n = 4 per group). d. Schematic showing transgenic
approach to monitor UPS impairment in vivo. UbG76V-GFP transgenic mice over-express a modified green fluorescent protein (GFP) constitutively
targeted for ubiquitin-dependent proteasome degradation. Under physiological conditions GFP is immediately degraded by the proteasome and
no intracellular accumulation of GFP can be detected; however, if UPS function is compromised, GFP accumulates inside the cell where it can be
detected. e. Representative photomicrographs (5x lens) showing subfield-specific increased GFP-reporter accumulation in the ipsilateral hippo-
campus of transgenic UbG76V-GFP mice subjected to intra-amygdala KA induced status epilepticus. Note, strong GFP signal in the DG and CA1
hippocampal subfield shortly after status epilepticus (4 h and 8 h) and scattered GFP staining throughout the hippocampus involving all subfields
24 h after seizure suppression. Scale bar, 500 μm f. Table showing hippocampal (DG, CA1 and CA3) subfield-specific increase in GFP signal in
transgenic UbG76V-GFP mice after status epilepticus. Subfield-specific GFP signal was quantified according to a semi-quantitative scale after staining
with GFP antibody (− baseline (absent/very low signal), + increase above baseline, ++ strong increase above baseline; n = 3 per group)
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accumulation of polyubiquitinated conjugates in the
hippocampus (Fig. 1c).
Subfield-specific UPS impairment in the hippocampus
after status epilepticus
To explore when and where UPS impairment occurs in
the hippocampus after status epilepticus, we made use of
an UPS reporter mouse expressing modified GFP
(UbG76V-GFP). In this model, GFP is constitutively tar-
geted for ubiquitin-dependent degradation by the prote-
asome through a ubiquitin fusion degradation (UFD)
signal consisting of an N-terminal linked ubiquitin moi-
ety accepting polyubiquitination chains thereby targeting
GFP for its rapid degradation by the proteasome [38]
(Fig. 1d). As reported previously, control UbG76V-GFP mice
showed a low number of GFP-positive cells detected by
antibodies against GFP [39], with basal GFP staining most
evident in the CA1 subfield of the hippocampus (Fig. 1e
and f). Analysis of hippocampal subfield-specific GFP
mRNA transcription and chymotrypsin-like proteasome ac-
tivity under basal conditions showed that this was inde-
pendent of differences in GFP transcription or intrinsic
proteasome activity (Additional file 1: Figure S2A, B). In
contrast, UbG76V-GFP mice subjected to status epilepticus
showed a strong increase in GFP immunoreactivity
throughout the hippocampus (Fig. 1e). Unexpectedly, an in-
creased GFP signal was first observed 4 and 8 h after status
epilepticus in the ipsilateral DG and CA1 subfields, brain
regions normally resistant to seizure-induced cell death in
the model (Fig. 1e and f). In contrast, GFP levels in CA3,
the region most damaged after intra-amygdala KA injection
[36], showed only a modest increase 8 h after status epilep-
ticus (Fig. 1e and f). The pattern of GFP staining later
changed dramatically, becoming diffuse throughout the
hippocampus by 24 h and no longer showing distinct
borders around neuronal populations (Fig. 1e). Thus,
UPS inhibition seems to be most prominent in hippo-
campal subfields spared from seizure-induced cell death
and appears to progress through different hippocampal
subfields involving different cell types over time follow-
ing status epilepticus.
Immunohistochemical findings were confirmed by
Western blotting using microdissected hippocampal
subfields from a separate set of UbG76V-GFP mice sub-
jected to status epilepticus. Consistent with the immuno-
histochemistry, GFP first increased in DG and CA1 8 h
post-status epilepticus with the most prominent GFP in-
crease in the DG (>20-fold) (Fig. 2a). At 24 h after status
epilepticus, GFP signal was increased in all hippocampal
subfields including CA3 (Fig. 2a).
To assure that the subfield-specific increase in
UbG76V-GFP protein in fact reflects a diminished UPS
function, we analyzed microdissected hippocampal sub-
fields from wild-type C57/Bl6 mice subjected to KA-
induced status epilepticus. As shown before for UbG76V-
GFP mice, polyubiquitination levels were increased in all
subfields with highest levels in the damage-protected
hippocampal subfields DG and CA1 (Fig. 2b).
Glutamate-induced excitotoxicity has been shown to re-
duce proteasome activity [24]. To determine whether the
seizure-induced UPS impairment is due to a decrease in
proteasome activity, proteasome catalytic activity assays
were performed. To rule out that intrinsic variations in
proteasome activity are the cause of the observed subfield
specific response to seizures, chymotrypsin-like activity
was compared between the different hippocampal sub-
fields CA1, DG and CA3 in naive C57/Bl6 wild-type mice.
No differences between the different hippocampal sub-
fields in chymotrypsin-like proteasome activity were ob-
served (Additional file 1: Figure S2A). We then subjected
wild-type mice to KA-induced status epilepticus and mea-
sured chymotrypsin-like proteasome activity in all differ-
ent hippocampal subfields at different time-points post
KA injection. No changes in chymotrypsin-like prote-
asome activity could be observed at the time of lorazepam
injection, 40 min after intra-amygdala KA injection when
analyzing all three hippocampal subfields (Additional file
1: Figure S2C); however, a small decrease in
chymotrypsin-like proteasome activity was evident 4 h
post status epilepticus in the CA1 subfield of the hippo-
campus (Fig. 2c). This was most likely due to changes in
the catalytic activity of the 20S proteasome itself, as no
changes in hippocampal 20S proteasome levels could be
observed after status epilepticus (Additional file 1: Figure
S2D). To test whether changes in GFP transcription might
be the cause of increased GFP protein levels after status
epilepticus we measured GFP transcripts at two different
time-points in the hippocampal subfields DG, CA3 and
CA1 (Fig. 2d). Only a minor, non-significant increase in
GFP transcripts 4 h and 24 h post-status epilepticus could
be observed which was present in all three hippocampal
subfields (Fig. 2d). No differences could be observed in
the magnitude of increase between the different hippo-
campal subfields, ruling out that increased GFP transcrip-
tion accounts for the differences observed in GFP protein
levels between hippocampal subfields (Fig. 2d).
UPS impairment in the undamaged contralateral
hippocampus after status epilepticus
To obtain further evidence of proteasome inhibition be-
ing a characteristic of damage- resistant brain areas, we
analysed the contralateral hippocampus of UbG76V-GFP
reporter mice subjected to intra-amygdala KA-induced
status epilepticus. Previous studies have confirmed, while
being protected from seizure-induced cell death, contra-
lateral hippocampal structures are recruited during
status epilepticus, however, to a lesser extent [40]. As
previously shown in Fig. 1e, UbG76V-GFP signal in the
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contralateral hippocampus was low in control vehicle-
injected animals with highest levels observed in the CA1
subfield (Fig. 3a). However as seen before, GFP levels in-
creased sharply in the contralateral hippocampus after
status epilepticus (Fig. 3a and b). This increase was most
evident in the DG (~5-fold) at early time-points. Scattered
GFP staining throughout the contralateral hippocampus
appeared 24 h after seizure suppression (Fig. 3a). Im-
munohistological results were supported by Western blot-
ting against GFP using tissue extracts from the three
contralateral hippocampal subfields DG, CA3 and CA1
(Fig. 3b). Western blotting using the polyubiquitination-
recognizing antibody FK2 [41] confirmed increased polyu-
biquitination in the contralateral hippocampus post-status
epilepticus (Fig. 3c). No changes in GFP mRNA levels
could be observed for the different subfields ruling out
increased GFP transcription being responsible for the
increase in GFP protein (Fig. 3d). These results confirm
UPS impairment as a global response in the brain to pro-
longed seizure activity.
Fig. 2 Subfield-specific UPS impairment after status epilepticus in the hippocampus. a. Representative Western (n= 1 per lane) and graphs showing
increased GFP protein in the different ipsilateral hippocampal subfields DG, CA1 and CA3 at different time-points following status epilepticus in UbG76V-GFP
mice (mean ± sem, *p<0.05 by one-way ANOVA with Fisher’s post hoc test; n= 4 (0 h), 5 (24 h) and 6 (Con, 1 h, 4 h and 8 h)). b. Representative Western
(n= 1 per lane) showing increased polyubiquitination (FK2 antibody) in C57/Bl6 wild-type mice after status epilepticus which is most prominent in the DG
and CA1 subfield. c. Graph showing decreased chymotrypsin-like proteasome activity in the CA1 subfield of C57/Bl6 wild-type mice 4 h after status epilepti-
cus when compared to control-injected mice. No changes could be observed in the remaining subfields DG (p= 0.289) and CA3 (p= 0.291) at the same
time-point post-status epilepticus (4 h) (mean ± sem, **p<0.01 by student’s two-tailed t-test; n= 8 (Con, Control) and 6 (SE, status epilepticus) per group). d.
Graphs showing no significant changes in GFP mRNA levels 4 h and 8 h after status epilepticus for the ipsi-lateral hippocampal subfields DG, CA1 and CA3
(mean ± sem, by one-way ANOVA with Fisher’s post hoc test; n= 4 per group). ns = non-significant
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Fig. 3 (See legend on next page.)
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Cell-specific UPS impairment after status epilepticus
To identify the cell types in which UPS inhibition oc-
curred, we performed immunofluorescence staining
using antibodies against GFP and specific cell markers
for neurons (NeuN), astrocytes (GFAP) and microglia
(CD11b). Double-staining of GFP and NeuN revealed a
mainly neuronal GFP accumulation at early time-points
post-status epilepticus (Fig. 4a and b). Co-localization of
GFP with the glial marker GFAP was essentially absent
at these early time-points (Fig. 4d). However, co-
localization with the astrocyte marker GFAP increased
sharply at later stages after status epilepticus (24 h and
72 h post-status epilepticus) (Fig. 4c and d) with ~50%
of GFAP-positive cells being positive for GFP (Fig. 4d).
We also observed co-localization of GFP with the inter-
neuron marker Parvalbumin (PV) (Fig. 4e) and occa-
sional co-localization of GFP with the microglial marker
CD11b at later time-points after status epilepticus (24 h)
(Fig. 4f ). These results suggest that status epilepticus
leads to a cell-specific UPS impairment, switching from
an early UPS impairment in neurons to appear at later
stages in glial cells, in particular astrocytes.
Proteasome inhibition in experimental epilepsy
Next, we explored whether UPS impairment also occurs
once epilepsy is established. However, the lack of suitable
control material (e.g. autopsy) prevented a full analysis of
UPS changes in patient tissue (note: polyubiquitination
levels rapidly decrease due to a post-mortem effect likely at-
tributed to the depletion of ATP required for Ub activation
[11]; Additional file 1: Figure S3A). Accordingly, we focused
our analysis on tissue from the intra-amygdala KA model.
In this model, all mice develop spontaneous recurrent sei-
zures within three to five days post-status epilepticus with
animals typically experiencing one to four epileptic seizures
per day [36]. Western blot analysis using the polyubiquiti-
nated substrate recognizing antibody FK2 revealed an in-
crease in hippocampal polyubiquitination levels in samples
from epileptic mice at day 14-post KA injection (Fig. 5a).
To test whether the accumulation of polyubiquitinated con-
jugates is accompanied by reduced proteasome activity,
chymotrypsin-like proteasome activity was assessed in hip-
pocampal lysates from epileptic C57/Bl6 wild-type mice.
Unexpectedly, and in contrast to what was observed after
status epilepticus, hippocampal tissue from epileptic mice
showed increased chymotrypsin-like activity (Fig. 5b). How-
ever, this may have been due to increased expression levels
of 20S proteasome subunits (Additional file 1: Figure S3B).
To identify cell types experiencing UPS inhibition in
epileptic mice, we analyzed tissue sections from UbG76V-
GFP reporter mice 14 days after status epilepticus. Here,
neurons of the DG were the main cell-population dis-
playing increased GFP levels (Fig. 5c). At this time-
point, co-localization between GFP and GFAP-positive
astrocytes was almost absent (Fig. 5c).
Proteasome inhibition can protect damage-vulnerable
hippocampal subfields against seizure-induced cell death
To establish whether proteasome inhibition can protect
neurons from excitotoxicity, primary hippocampal neu-
rons were treated with different concentrations of two
different proteasome inhibitors, epoxomicin [42] and
MG132 [43] before being exposed to a cell death-
causing concentration of KA (0.3 μM) [44]. Consistent
with proteasome inhibition being protective, epoxomicin
pre-treated hippocampal neurons showed significantly
less cell death when compared to vehicle-treated
primary hippocampal neurons (Fig. 6a). Protection was
most obvious at lower doses of epoxomicin (1 nM).
The protection still persisted at higher doses of epoxo-
micin (10 nM), however, to a lesser extent. This was
possibly due to neurotoxic effects of proteasome inhib-
ition [8, 45] (Fig. 6a). To test whether protection is specific
to epoxomicin, we used MG132, which belongs to a differ-
ent class of proteasome inhibitors [43]. As observed for
epoxomicin, MG132 treatment protected neurons from
cell death (Fig. 6b). Again, this neuroprotective effect was
more pronounced at lower concentrations of MG132
(Fig. 6b) mirroring the effect of epoxomicin. Finally, to
show that this protection was not specific to the KA in
vitro model, primary hippocampal neurons were treated
with a cell death-causing dose of potassium (25 mM). As
observed before with KA, pre-treatment with epoxomicin
protected against potassium-induced cell death in vitro
(Fig. 6c).
Next, to explore whether proteasome inhibition is
neuroprotective in vivo against status epilepticus, C57/
Bl6 wild-type mice were pre-treated with the proteasome
(See figure on previous page.)
Fig. 3 UPS impairment in the contralateral hippocampus after status epilepticus. a. Representative photomicrographs (5x lens) showing subfield-specific
increased GFP-reporter accumulation in the contralateral hippocampus of transgenic UbG76V-GFP mice subjected to intra-amygdala KA-induced status
epilepticus. Note, similar GFP staining pattern as observed in the ipsilateral hippocampus. Scale bar, 500 μm. b. Representative Western (n= 1 per lane) and
graphs showing increased GFP levels in the contralateral hippocampal subfields DG, CA1 and CA3 after status epilepticus (mean ± sem, *p<0.05 by one-
way ANOVA with Fisher’s post hoc test; n= 4 per group). c. Representative Western (n = 1 per lane) and graph showing increased polyubiquitina-
tion levels (FK2 antibody) in the contralateral hippocampus after intra-amygdala KA induced-status epilepticus (mean ± sem, *p <0.05 by
one-way ANOVA with Fisher’s post hoc test; n = 4 per group). d. Graphs showing no significant changes in GFP mRNA levels 4 h and 8 h after
status epilepticus for the contralateral hippocampal subfields DG, CA1 and CA3 (mean ± sem, by one-way ANOVA with Fisher’s post hoc test; n = 4 per
group). ns = non-significant
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Fig. 4 (See legend on next page.)
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(See figure on previous page.)
Fig. 4 Cell-specific UPS impairment after status epilepticus. a. Representative photomicrographs (5x lens) of coronal cut hippocampal brain slices from
UbG76V-GFP reporter mice double stained against GFP (green) and the neuronal marker NeuN (red) at different time-points post-status epilepticus. Scale
bar, 500 μm. b. Representative photomicrographs (40x lens) showing co-localization between the neuronal marker NeuN (red) and GFP (green) in the
hippocampal subfields DG, CA1 and CA3 4 h post-status epilepticus in UbG76V-GFP reporter mice. Scale bar, 50 μm. c. Representative photomicrographs
(40x lens) showing co-localization between the astrocyte marker GFAP (red) and GFP (green) in the ipsilateral hippocampal subfields DG, CA1 and CA3
24 h and 72 h post-status epilepticus in UbG76V-GFP reporter mice. Scale bar, 50 μm. d. Graph showing percentage of hippocampal astrocytes positive
for GFP after the induction of status epilepticus (mean ± sem, **p <0.01 by one-way ANOVA with Fisher’s post hoc test; n = 4 per group). e. Representa-
tive photomicrograph (40 x lens) showing co-localization between GFP (green) and the inter-neuronal marker parvalbumin (PV) (red) in the hilar sub-
region of the ipsilateral hippocampus of UbG76V-GFP reporter mice 24 h post-status epilepticus. Scale bar, 50 μm. f. Representative photomicrograph (40
x lens) showing co-localization between GFP (green) and the microglial marker CD11b (red) in the CA3 ipsilateral hippocampal subfield of UbG76V-GFP
reporter mice 24 h post-status epilepticus. Scale bar, 50 μm
Fig. 5 UPS impairment during epilepsy. a. Representative Western (n = 1 per lane) and graph showing increased polyubiquitination (FK2) in the
ipsilateral hippocampus of epileptic C57/Bl6 wild-type mice 14 days post-intraamygdala KA (mean ± sem, *p <0.05 by one-way ANOVA with Fish-
er’s post hoc test; n = 4 per group). b. Increased chymotrypsin-like proteasome activity in the ipsilateral hippocampus of epileptic C57/Bl6
wild-type mice 14 days post-intraamygdala KA (mean ± sem, *p <0.05 by student’s two-tailed t-test; n = 4 per group). c. Representative
photomicrograph (40 x lens) showing co-localization between GFP (green) and the neuronal marker NeuN (red) in the different hippocampal subfields
of the ipsilateral hippocampus of UbG76V-GFP reporter mice 14 days post-status epilepticus which was most evident in the DG (arrows). Co-localization
of GFP with the astrocyte marker GFAP (red) in the same mice was mainly absent. Scale bar, 50 μm
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Fig. 6 (See legend on next page.)
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inhibitor epoxomicin 30 min before the injection of KA.
Proteasome activity assays, Western blotting and immu-
nostaining against GFP confirmed hippocampal UPS in-
hibition after intracerebroventricular (i.c.v.) delivery of
epoxomicin (Additional file 1: Figure S4A - C). Mice
which received 100 μM i.c.v. epoxomicin prior to intra-
amygdala KA injection displayed significantly less neuro-
degeneration in the ipsilateral hippocampal subfield CA3
when compared to vehicle-injected mice as assessed by
FjB staining 24 h after status epilepticus (Fig. 6d). To test
whether a more severe seizure model, with more exten-
sive CA3 damage, would alter the protective effects of
epoxomicin, we used a second model of status epilepti-
cus displaying predominant necrotic cell death [46]. As
observed before, epoxomicin-treated mice displayed less
cell death in the ipsilateral CA3 after status epilepticus
when compared to vehicle-injected mice (Fig. 6e) further
confirming the neuroprotective potential of proteasome
inhibition against seizure-induced cell death. Finally, to
rule out any possible effects of differences in seizure se-
verity on seizure-induced cell death, we analyzed high
amplitude high frequency discharges, synonymous with
injury-causing electrographic activity [47], during the
time from KA injection until the administration of the
anticonvulsant lorazepam. All treatment groups under-
went similar seizure severity and seizure-induced behav-
iour changes (Fig. 6f-h) suggesting neuroprotection was
not secondary to an anticonvulsant effect of epoxomicin.
Discussion
In the present study we show an increased accumulation
of polyubiquitinated proteins in the hippocampus after
prolonged seizures and during epilepsy suggesting a
seizure-induced inhibition of the UPS. Most strikingly and
unexpectedly, seizure-induced UPS impairment was
mainly evident in brain areas resistant to seizure-induced
cell death including neurons and astrocytes. In line with a
neuroprotective role of proteasome inhibition during sei-
zures, mice treated with the specific proteasome inhibitor
epoxomicin displayed less neurodegeneration. These find-
ings support proteasome inhibition as an endogenous pro-
tective mechanism against seizure-induced cell death.
Despite differences in disease etiology (e.g. β-amyloid,
polyglutamine expansion, neurodevelopmental abnor-
malities and other) several chronic brain disorders share
common clinical symptoms (e.g. cognitive deficits, sei-
zures and psychological problems such as depression
and anxiety) implying the emerging concept of existing
shared pathological pathway activation among different
brain diseases [48–50]. Proteasome inhibition and the
accumulation of polyubiquitinated aggregates are a com-
mon characteristic of chronic neurodegenerative diseases
such as Alzheimer’s and Huntington’s [9, 51] and an im-
pairment of the UPS has also been reported after acute
insults to the brain such as stroke and traumatic brain
injury [10, 52]. Likewise, emerging evidence suggests a
dysfunction of the UPS in neurological diseases such as
epilepsy [29]. However, previous studies lacked evidence
showing a direct link between seizures and proteasome
inhibition and whether seizures lead to an inhibition of
the proteasome in vivo has not been fully established.
Studies were limited to determining the expression levels
of specific subunits of the immunoproteasome [28, 29]
or to identify the impact certain mutations of genes in-
volved in UPS functions have on pathology (e.g. different
E3 ligases, deubiquitinating proteins) [26, 31]. Recent in
vitro experiments have suggested that glutamate-
induced excitotoxicity may lead to UPS inhibition medi-
ated by NMDA receptor activation [24]. We extend
these studies here by showing that prolonged seizures
lead to an impairment of the UPS with the subsequent
accumulation of polyubiquitinated substrates in the
(See figure on previous page.)
Fig. 6 Proteasome inhibition protects from seizure-induced cell death. a Graph showing decreased KA-induced cell death in hippocampal primary
neurons when pre-treated with the specific proteasome inhibitor epoxomicin (mean ± sem, *p <0.05, **p <0.01 and ***p <0.001 by one-way
ANOVA with Fisher’s post hoc test; n = 3 per group). b. Decreased KA-induced cell death in hippocampal primary neurons when pre-treated with
the specific proteasome inhibitor MG132 (mean ± sem, *p <0.05 by one-way ANOVA with Fisher’s post hoc test; n = 4 per group). c. Epoxomicin
pre-treatment protects against cell death caused by increased extracellular [K+] (25 mM) in primary hippocampal cultures (mean ± sem, *p <0.05 by
one way ANOVA with Fisher’s post hoc test; n = 3 per group). d. Graph and representative images of the CA3 region of the ipsilateral hippocampus
showing decreased seizure-induced cell death in mice pretreated with epoxomicin. Status epilepticus was induced by an intra-amygdala injection of
0.3 μg KA and neuronal cell death was assessed 24 h later by counting FjB-positive cells in the ipsilateral hippocampal subfield CA3 (mean ± sem, *p
<0.05 by one-way ANOVA with Fisher’s post hoc test; n = 11 (Control), 5 (30 and 300 μM epoxomicin) and 7 (100 μM epoxomicin). Scale bar, 50 μm. e.
Pre-treatment with epoxomicin protects against seizure-induced cell death in a model of predominant necrotic cell death. Here, status epilepticus was
induced by an intra-amygdala injection of 1.0 μg KA and neurodegeneration analyzed by counting FjB-positive cells in the hippocampal subfield CA3
24 h post-KA injection (mean ± sem, *p <0.05 by student’s two-tailed t-test; n = 4 (Control) and 5 (100 μM epoxomicin). f. Similar amount of high ampli-
tude and high frequency polyspiking in mice subjected to status epilepticus during a recording period of 40 min pre-treated with different concentra-
tions of epoxomicin (analysis started at time-point of intra-amygdala KA (0.3 μg) injection until lorazepam administration) (mean ± sem, *p <0.05 by
ANOVA with Fisher’s post hoc test; n = 8 (Control), 5 (30 μM), 7 (100 μM) and 6 (300 μM)). g. Representative electroencephalogram (EEG) traces during
status epilepticus from mice treated with vehicle or 100 μM epoxomicin showing similar high frequency and high amplitude polyspiking. h. Graph
showing no significant differences in clinical seizures during the time of intra-amygdala KA (0.3 μg) injection until lorazepam administration between
mice pre-treated with vehicle or 100 μM epoxomicin (mean ± sem, by two-way ANOVA with Bonferroni post hoc test; n = 5 per group)
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brain. We do not know what causes an inhibition of the
proteasome after seizures. In line with in vitro results
[24], we have observed a down-regulation of
chymotrypsin-like activity in the hippocampal subfield
CA1 after KA-induced seizures. This may contribute to
the accumulation of polyubiquitinated proteins in the
hippocampus after seizures. However, the hippocampal
subfield showing the strongest increase of UbG76V-GFP
reporter protein levels and polyubiquitinated conjugates
after status epilepticus in our model was the DG subfield
which showed only a marginal inhibition of the catalytic
activity of the 20S proteasome. Previous studies have
shown a dose-dependent increase in UbG76V-GFP re-
porter in hippocampal neurons treated with epoxomicin
[35], therefore, our results suggest that other mecha-
nisms may contribute to proteasome inhibition. More-
over, no differences in 20S proteasome activity was
observed at the time of lorazepam administration, fur-
ther suggesting only a small contribution of the catalytic
down-regulation of the 20S proteasome to UPS impair-
ment. Other factors may contribute to the accumulation
of polyubiquitinated proteins after prolonged seizures.
Status epilepticus leads to a depletion of intracellular
ATP [53], possibly impeding E1-mediated Ub activation
and compromising a correct functioning of the ATP-
consuming 20S proteasome [11]. Increased intracellular
Ca2+ during excitotoxicity might also lead to a dysfunc-
tion of the proteasome [24]; however, other reports
have suggested that increased intracellular Ca2+ levels
lead to increased proteasome activity [54]. Further-
more, status epilepticus leads to an increase in ER-
stress [55] and an impairment of autophagy [56], a sec-
ond major intracellular protein-degrading mechanism,
thereby potentially leading to an overload of substrates
which exceeds the capacity of the proteasome. Regard-
less of the mechanism, our results show that seizures
lead to an impairment of the UPS with the subsequent
accumulation of poly-ubiquitinated substrates in the
hippocampus. Interestingly, seizures are a common co-
morbidity of many neurodegenerative diseases such as
Alzheimer’s and Huntington’s [57, 58] possibly contrib-
uting to the accumulation of polyubiquitinated aggre-
gates during these diseases.
Our second major finding was that proteasome inhib-
ition was most evident in hippocampal subfields resist-
ant to seizure-induced cell death. This was unexpected
since proteasome inhibition is typically associated with a
failure of homeostasis and a driver of neurodegeneration
[8]. We do not know why UPS impairment was most
evident in these brain regions. However, comparing GFP
increases between both brain hemispheres and the dif-
ferent hippocampal subfields, it is tempting to speculate
that the level of proteasome inhibition reflects seizure
progression throughout the ipsilateral and contralateral
hippocampus [40] with the DG being the major site of
excitatory input into the hippocampus [59]. While prote-
asome inhibition was most apparent in neurons at early
stages after status epilepticus, astrocytes were the main
cell population affected later by UPS impairment. This
might be due to the fact that neurons are most likely the
cell population activated during the early stages of
seizure-induced pathology, while glial responses occur at
later stages [60]. Interestingly, proteasome inhibition has
been shown to decrease astrogliosis in vitro and in vivo
[61]. Furthermore, recent studies demonstrated that
astrogliosis alone, in the absence of any other pathology,
is sufficient to cause epilepsy in mice [62, 63]. This may
suggest a potential anti-epileptic effect provided by pro-
teasome inhibition in glia. UPS impairment in astrocytes
is not unique to our seizure model and has been de-
scribed for other diseases including Huntington’s disease
[64]; amyotrophic lateral sclerosis [65] and prion disease
[39]. Moreover, astrocytes seem to be well adapted to
support long-lasting UPS impairment probably due to
the efficient induction of heat shock responses [66].
Why does the ipsilateral CA3 subfield of the hippo-
campus display a delayed inhibition of the UPS? The
CA3 subfield is particularly vulnerable in our model [36]
possibly due to the high density of kainate receptors
[67]. Although a NMDA-mediated down-regulation of
the UPS has been observed after excitotoxicity [24], this
has been restricted to the nuclear compartment [24]. On
the other hand, increased intracellular Ca2+ concentra-
tions have been shown to activate the proteasome [54]
which may delay the accumulation of polyubiquitinated
conjugates at early time-points after status epilepticus.
Another possible explanation for the delayed accu-
mulation of polyubiquitinated proteins in CA3 may be
increased inhibition of translation after seizures [68]
leading to fewer substrates to be degraded by the
proteasome.
Although the spatio-temporal profile of UPS inhibition
has not been reported previously after status epilepticus,
there have been numerous reports of UPS inhibition
after ischemic brain injury [27, 69, 70]. Here, proteasome
inhibition was most evident in the hippocampal subfield
CA1, a brain region vulnerable to ischemia-induced cell
death, whereas only a transient polyubiquitination could
be observed in the remaining cell-death resistant hi-
ppocampal subfields CA3 and DG [27]. This is different
to status epilepticus, where, in contrast to ischemia, cell
death-resistant brain regions showed the highest in-
crease in polyubiquitination levels, suggesting a unique
pathology according to brain insult. Interestingly, during
ischemia the hippocampal subfield CA1 showed the
strongest reduction in the catalytic activity of the prote-
asome [71], similar to findings in our mouse model of
status epilepticus, suggesting that some similarities may
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exist between different conditions. We do not know why
the hippocampal subfield CA1 is more prone to a reduc-
tion in proteasome activity after seizures and why this
downregulation is not accompanied by a bigger increase
in polyubiquitinated proteins after status epilepticus
when compared to the other hippocampal subfields. Dif-
ferences in glutamate receptor recruitment during status
epilepticus (e.g. NMDA subtype vs. kainic acid or AMPA
receptor) with the resulting differences in intracellular
calcium levels, may affect proteasome activity [24, 54].
Differences in the subfield-specific clearance of damaged
proteins and/or ER-stress during status epilepticus might
also contribute to differences in the accumulation of
polyubiquitinated proteins.
Why does UPS impairment protect against seizure-
induced cell death? The protection is presumably a re-
sult of an accumulation of proteins that would otherwise
be degraded. However, we do not know their identity.
The most likely candidates probably include proteins in-
volved in inflammatory processes such as NFκB which
has been shown to mediate proteasome inhibitor-
mediated neuroprotection after ischemia [72, 73]. Other
proteins such as heat shock proteins [74] or synaptic
proteins may also be involved. This could be assessed in
the future using Tandem mass spectrometry (MS-MS)-
type approaches. Another option may be that accumu-
lated proteins interrupt signalling pathways that would
normally be able to progress through to kill neurons or,
alternatively, the inhibition of the ATP-consuming UPS
may help protect against excessive depletion of energy
reserves during seizures.
Emerging evidence suggests that the UPS controls
neurotransmission by regulating crucial processes such as
synaptic plasticity, spinogenesis and levels of functional
neurotransmitter receptors [17]. We have not observed
any changes in seizure severity during status epilepticus
after epoxomicin treatment. However, a potential impact
of the proteasome on seizure generation or seizure sever-
ity might be more important under chronic conditions.
Epileptic mice in our study showed increased polyubiqui-
tination levels in the hippocampus suggesting a chronic
impairment of the UPS which may contribute to hyperex-
citability. In line with this, recent data has shown a more
severe epileptic phenotype in rats treated with the prote-
asome inhibitor MG-132 [75], which, in contrast to
epoxomicin, also inhibits calpain activity [76]. While
acute/transient UPS inhibition may be protective, long-
lasting inhibition may be neurotoxic. Indeed, inhibition
of the UPS has been reported to elicit neurode-
generation directly [8, 45]. Therefore, it is unlikely pro-
teasome inhibitors will be used as neuroprotective or
anti-epileptic drugs. However, they provide important
insight into molecular pathogenesis and, if we can iden-
tify the affected pathways/proteins involved, this may
lead to novel approaches for the treatment of status ep-
ilepticus and epilepsy.
Conclusions
Our data show that prolonged seizures lead to an impair-
ment of the UPS which is most prominent in brain areas
resistant to seizure-induced cell death suggesting prote-
asome inhibition as an endogenous protective mechanism.
Methods
Mouse seizure models
For our studies we used adult male mice (20–25 g) (C57Bl/
6 (Harlan laboratories, Bicester, UK)) and mice ubiquitously
expressing the ubiquitin fusion degradation substrate ubi-
quitinG76V-green fluorescent protein (UbG76V-GFP) [38].
The main experiments used the intra-amygdala KA-
induced status epilepticus [36]. Briefly, mice were anesthe-
tized using isoflurane (3–5%) and maintained normother-
mic by means of a feedback-controlled heat blanket
(Harvard Apparatus Ltd, Kent, England). Then, mice were
placed in a stereotaxic frame and following a midline scalp
incision, three partial craniotomies were performed. Surface
EEG was recorded from three scull-mounted recording
electrodes (Bilaney Consultants Ltd, Sevenoaks, UK) placed
above the dorsal hippocampus and frontal cortex. EEG was
recorded using a Grass Comet digital EEG (Medivent Ltd,
Lucan, Ireland). A guide cannula was affixed over the dura
(coordinates from Bregma: AP = −0.94; L = −2.85 mm) and
the entire skull assembly fixed in place with dental cement.
Anaesthesia was discontinued, EEG recordings were com-
menced, and then a 31-gauge internal cannula (Bilaney
Consultants Ltd, Sevenoaks, UK) was inserted into the
lumen of the guide to inject KA (Sigma-Aldrich, Dublin,
Ireland) (0.3 μg in 0.2 μl of vehicle or 1.0 μg in 0.2 μl of ve-
hicle; phosphate-buffered saline (PBS), pH adjusted to 7.4)
into the amygdala. Non-seizure control animals received
the same volume of intra-amygdala vehicle. EEG was
recorded until intra-peritoneal lorazepam (6 mg/kg) ad-
ministration at 40 min post-KA injection. In a sub-
group of mice, status epilepticus was induced by a
subcutaneous injection of pilocarpine (Sigma-Aldrich,
Dublin, Ireland) at 340 mg/kg body weight, 20 min
after injection of methyl-scopolamine (1 mg/kg)
(Sigma-Aldrich, Dublin, Ireland) [40].
Mice were euthanized at different time-points post lor-
azepam administration (0, 1, 4, 8, 24 and 72 h and 7 and
14 days) by transcardial perfusion with PBS or 4% para-
formaldehyde (PFA) or brains were microdissected on
ice and processed for protein analysis.
Quantification of EEG and behaviour assessment of
seizure severity
Cortical EEG recordings were analyzed off-line using
manual assessment as described [77]. The duration of
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high-frequency (>5 Hz) and high-amplitude (>2X base-
line) polyspike discharges of ≥5 s duration (HAHFDs)
which are synonymous with injury-causing electro-
graphic activity [47] was counted by a reviewer blind to
treatment. Changes in seizure-induced behaviour were
scored according to a modified Racine Scale as reported
previously [78]. Score 1, immobility and freezing; Score
2, forelimb and or tail extension, rigid posture; 3, repeti-
tive movements, head bobbing; Score 4, rearing and fall-
ing; Score 5, continuous rearing and falling; Score 6,
severe tonic–clonic seizures. Mice were scored every
5 min for 40 min after KA injection. The highest score
attained during each 5 min period was recorded by an
observer blinded to treatment.
In vivo drug treatments
Drugs were delivered via intracerebroventricular (i.c.v.)
injections as described before [77] (coordinates for i.c.v.
injections were Bregma: AP = −0.3 mm, L = −1.0 mm, V =
−2.0 mm). Mice received a 2 μl infusion of the specific pro-
teasome inhibitor epoxomicin (Sigma-Aldrich, Dublin,
Ireland) at 30 μM, 100 μM or 300 μM (diluted in 100%
dimethyl sulphoxide, (Sigma-Aldrich, Dublin, Ireland) or
vehicle 30 min before the induction of status epilepticus
and 60 min after KA injection.
Proteasome activity assay
To measure chymotrypsin-like proteasome activity, we
used the fluorigenic peptide N-succinyl-Leu-Leu-Val-Tyr-7-
amino-4-methyl-coumarin (suc-LLVYAMC) (Calbiochem,
Nottingham, UK). Tissue or cells were homogenised in lysis
buffer (10 mM HEPES, 42 mM KCl, 5 mM MgCl2,
0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5% (w/v)
CHAPS). Then, lysates were incubated with reaction buffer
(25 mM HEPES, pH 7.4, 0.5 mM EDTA, pH 8) containing
suc-LLVY-AMC. Using 360 nm excitation, fluorescence
was measured at 465 nm and 37 °C using a plate reader
with the appropriate filters (GENios, Tecan, Weymouth,
UK). Fluorescence signals were normalized to the protein
concentrations, which were determined by Bradford assay
(Thermo Fisher Scientific, Dublin, Ireland).
Western blotting
Western blotting was performed as previously described
[40]. Whole hippocampi or hippocampal subfields (den-
tate gyrus (DG), CA1 and CA3) were homogenized in
lysis buffer and protein concentration was determined.
30 μg protein samples were boiled in gel-loading buffer
and separated on 10% to 12% SDS-PAGE gels. Proteins
were transferred onto nitrocellulose membranes (BioRad,
Hercules, USA) and then incubated with antibodies
against the following: GFP (1/500, Cell Biolabs, CA, USA,
AKR/020), FK-2 (polyubiquitin) (1/1000, Merck Millipore,
Billerica, MA, U.S.A), C-Fos (1/400, Santa Cruz
Biotechnology, CA, U.S.A), Proteasome 20S (1/1000, Enzo
Life Science, Exeter, UK), β-Actin (1/1000, Sigma-Aldrich,
Dublin, Ireland) and α-Tubulin (1/1000, Santa Cruz
Biotechnology, Heidelberg, Germany). Membranes were
then incubated with horseradish peroxidase-conjugated
secondary antibodies (Jackson Immuno Research, Plymouth,
PA) and bands visualized using Supersignal West Pico
Chemiluminescent Substrate (Pierce, Rockford, IL). Images
were captured using a Fuji-film LAS-300, densitometry per-
formed using AlphaEaseFC4.0 software and data expressed
as change relative to control.
RNA extraction and real time PCR
Total mRNA was extracted as previously described using
the Trizol protocol [40]. Quantity of mRNA was mea-
sured using a Nanodrop Spectrophotometer (Thermo
Fisher Scientific, Rockford, IL, USA) and RNA dilutions
were made up in nuclease-free water. For analysis of
mRNA expression, 1 μg of total RNA was used to gener-
ate cDNA by reverse transcription using a Superscript II
Reverse Transcriptase enzyme (Thermo-Fisher, MA,
USA). Quantitative real-time PCR was performed using
a LightCycler 1.5 (Roche Diagnostics GmbH, Mannheim,
Germany) in combination with QuantiTech SYBR Green
PCR kit (Qiagen, Hilden, Germany) as per the man-
ufacturer’s protocol and 1.25 μM of primer pair used.
Data were represented as 2−ΔΔCT and normalized to the
expression of β-actin. Primers used: GFP (F: acgtaaacggcca-
caacttc, R: aagtcgtgctgcttcatgtg); β-actin (F: gggtgtgatggtgg-
gaatgg, R: ggttggccttagggttcagg).
Histopathology
Neuronal damage was assessed by FjB (Merck Millipore,
CA, USA) as described before [77]. Briefly, fresh-frozen
coronal brain sections at the level of the dorsal hippocam-
pus were post-fixed in formalin for 30 min, then incubated
in 0.0006% potassium permanganate, washed and incu-
bated for 20 min with a 0.001% FJB solution (Chemicon
Europe Ltd., Chandlers Ford, UK). Once washed and
dried, slides were coverslipped with DPX mounting solu-
tion (Sigma-Aldrich, Dublin, Ireland). Counts were the
average of two adjacent sections assessed by an observer
blinded to treatment.
Immunofluorescence staining and confocal microcopy
For confocal microscopy, animals were transcardially
perfused with 4% PFA, post-fixed and embedded in 2%
agarose before sectioning on a vibratome (Leica Biosys-
tems, Wetzlar, Germany). Sections were rinsed and
treated with PBS containing 0.1% Triton™ X-100 and 1%
foetal calf serum followed by incubation with the pri-
mary antibodies; GFP (1/500, Life Technologies, Thermo
Fisher Scientific, Rockford, USA, A11122), NeuN (1/400;
Merck Millipore, Billerica, MA, U.S.A), GFAP (1/500,
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Santa Cruz Biotechnology, CA, U.S.A), Cd11b (1/400,
Abcam, Cambridge, UK) and PV (1/5000, Swant Inc,
Marly, Switzerland). Sections were washed again and in-
cubated with secondary antibodies coupled to Alexa
Fluor® 488 or Alexa Fluor® 568 (BioSciences Ltd, Dublin,
Ireland). Sections were then coverslipped with Fluoro-
save™ (Merck Millipore, Billerica, MA, U.S.A). Confocal
images were acquired with a Leica TCR 6500 microscope
equipped with four laser lines (405, 488, 561 and 653 nm)
using a × 40 immersion oil objective.
To determine the percentage of GFP-positive astrocytes,
sections were double-stained with antibodies detecting
GFP and the astrocyte marker GFAP. 6 pictures were
taken from each hippocampus (2 from each hippocampal
subfield) at 20x magnification and astrocytes positive for
GFAP alone or colocalized with GFP were counted in sec-
tions from control mice and at different timepoints post
status epilepticus (1 h, 4 h, 8 h, 24 h and 72 h after KA in-
jection). Images were analyzed using ImageJ.
Diaminobenzidine (DAB) immunohistochemistry
DAB staining was performed as described before [77].
Briefly, mice were anesthetized and transcardially per-
fused with 4% PFA. Brains were post-fixed in 4% PFA
and prepared for sectioning on vibratome as described.
Next, 30 μm sagital brain sections were pretreated for
1 h with 1% BSA, 5% FBS, and 0.2% Triton X-100, and
then incubated with the primary antibody GFP (1/500,
Life Technologies, Thermo Fisher Scientific, Rockford,
USA, A11122). Finally, brain sections were incubated in
avidin–biotin complex using the Elite Vectastain kit
(Vector Laboratories, Burlingame, CA, U.S.A). Chromo-
gen reactions were performed with diaminobenzidine
(Sigma-Aldrich, Dublin, Ireland) and 0.003% H2O2 for
10 min and, once dried, sections were coverslipped with
Fluorosave.
Primary hippocampal cell culture
Primary cultures of hippocampal neurons were prepared
from E18.5 embryonic C57/Bl6 wild-type mice as described
previously [40]. Briefly, neurons were plated onto poly-L-
lysine and laminin bed and maintained in Neurobasal
medium supplemented with B-27 and N2 (Biosciences,
Belgium), at 37 °C in a humidified atmosphere with 5% (v/
v) CO2 for 8 days. On in vitro day 8, cells were pre-treated
with different doses of epoxomicin (1, 5 and 10 nM) or
MG132 (Sigma-Aldrich, Dublin, Ireland) (1 and 5 μM) for
12 h. Cells were then treated with 0.3 μM KA or 25 mM
KCl for 6 h. Cell death was determined using Propidium
iodide (PI) (Sigma-Aldrich, MO, USA) staining. Cells were
stained with PI and Hoechst and a minimum of three pic-
tures were taken per experiment (20 x lens) blinded to
treatment. Cell death was calculated as percentage of PI
uptake in relation to Hoechst-positive cells. Each experi-
ment was obtained from an independent dam (n = 3).
Simulated post-mortem delay
To determine possible changes in UPS activity due to
post-mortem delay differences, hippocampi were ex-
tracted from mice (adult C57Bl/6) after deep anesthesia
with pentobarbital and decapitation. Hippocampi were ei-
ther frozen immediately (‘surgical’ control) or frozen 4 h
or 8 h after being left at room temperature (simulated
post-mortem interval). Samples were then processed for
Western blotting as described before [77].
Data analysis
All data are presented as mean ± standard error of the
mean. Two group comparisons were made using unpaired
Student’s two-tailed t-test, while multi-group comparisons
were made using one-way or two-way analysis of variance
(ANOVA) followed by post hoc testing using Fisher’s
exact test (StatView). Significance was accepted at P <0.05.
Additional file
Additional file 1: Supplemental Figures S1-S4 (DOC 604 kb)
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